Skip to content
Open access

Preclinical and First‐In‐Human Evaluation of Ribupatide (HRS9531), a Dual GLP‐1/GIP Receptor Agonist

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11643 - 11652 · 0 citations · 24 references
Medicine

Abstract

This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.